Between an Ugly Truth and a Perfect Lie: Wiping off Fearful Memories Using Beta-adrenergic Receptors Antagonists
Overview
Physiology
Affiliations
Psychiatric disorders such as anxiety, phobias, and post-traumatic stress disorder are considered of high global prevalence. Currently, a therapeutic approach to treat these disorders using beta-blockers, which antagonize the beta-adrenergic receptors (B1, B2, and B3) is being studied. This approach claims that beta-blockers, such as propranolol, inhibit fear memory reconsolidation. However, there are several studies refuting such claims by discrediting their experimental design and pointing out both the drugs pharmacokinetic properties and confounding factors. In this review, we explore the different effects of central beta-adrenergic agonists and antagonists on the fear memory consolidation providing mixed-evidence, limitations, and future directions.
Li H, Zhang Z, Yang S, Zhu G Front Pharmacol. 2025; 16:1545493.
PMID: 39944616 PMC: 11814184. DOI: 10.3389/fphar.2025.1545493.
From circuits to behavior: Amygdala dysfunction in fragile X syndrome.
Svalina M, Sullivan R, Restrepo D, Huntsman M Front Integr Neurosci. 2023; 17:1128529.
PMID: 36969493 PMC: 10034113. DOI: 10.3389/fnint.2023.1128529.
Perioperative Propranolol Against Dental Anxiety: A Randomized Controlled Trial.
Steenen S, Su N, van Westrhenen R, van Wijk A, Tjia D, de Lange J Front Psychiatry. 2022; 13:842353.
PMID: 35264990 PMC: 8899208. DOI: 10.3389/fpsyt.2022.842353.
Cardiovascular therapeutics: A new potential for anxiety treatment?.
Repova K, Aziriova S, Krajcirovicova K, Simko F Med Res Rev. 2022; 42(3):1202-1245.
PMID: 34993995 PMC: 9304130. DOI: 10.1002/med.21875.
β-blockers Reverse Agonist-Induced β-AR Downregulation Regardless of Their Signaling Profile.
Maccari S, Vezzi V, Barbagallo F, Stati T, Ascione B, Gro M Int J Mol Sci. 2020; 21(2).
PMID: 31947522 PMC: 7013648. DOI: 10.3390/ijms21020512.